Evidence map›Paper›PMID 35795202›Full record

ArticleFrontiers in genetics2022

Tumor Suppressor 4.1N/

Qin Yang, Lin Zhu, Mao Ye, Bin Zhang, Peihe Zhan, Hui Li, Wen Zou, Jing Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. LncRNA CALML3-AS1 modulated by mCancer gene therapy · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qin YangMolecular Biology Research Center and Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China.
Lin ZhuMolecular Biology Research Center and Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China.
Mao YeMolecular Science and Biomedicine Laboratory, College of Biology, College of Chemistry and Chemical Engineering, Collaborative Innovation Center for Chemistry and Molecular Medicine, Hunan University, Changsha, China.
Bin ZhangDepartment of Histology and Embryology, Xiangya School of Medicine, Central South University, Changsha, China.
Peihe ZhanDepartment of Histology and Embryology, Xiangya School of Medicine, Central South University, Changsha, China.
Hui LiMolecular Biology Research Center and Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China.
Wen ZouDepartment of Oncology, The Second Xiangya Hospital of Central South University, Central South University, Changsha, China.
Jing LiuMolecular Biology Research Center and Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China.
Central South University · CNHunan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small-cell lung cancer (NSCLC) is divided into three major histological types, namely, lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and large-cell lung carcinoma (LCLC). We previously identified that 4.1N/

Indexed as

4.1N/EPB41L1lung adenocarcinoma (LUAD)lung squamous cell carcinoma (LUSC)methylationmiR-454-3Pnon–small-cell lung cancer (NSCLC)

Identifiers

PMID35795202
PMCPMC9251189
OpenAlexW4283159255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.